Your browser doesn't support javascript.
The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections.
Moubarak, Mohamed; Kasozi, Keneth Iceland; Hetta, Helal F; Shaheen, Hazem M; Rauf, Abdur; Al-Kuraishy, Hayder M; Qusti, Safaa; Alshammari, Eida M; Ayikobua, Emmanuel Tiyo; Ssempijja, Fred; Afodun, Adam Moyosore; Kenganzi, Ritah; Usman, Ibe Michael; Ochieng, Juma John; Osuwat, Lawrence Obado; Matama, Kevin; Al-Gareeb, Ali I; Kairania, Emmanuel; Musenero, Monica; Welburn, Susan Christina; Batiha, Gaber El-Saber.
  • Moubarak M; Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, Egypt.
  • Kasozi KI; Infection Medicine, Deanery of Biomedical Sciences, College of Medicine and Veterinary Medicine, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.
  • Hetta HF; School of Medicine, Kabale University, Kabale P.O. Box 317, Uganda.
  • Shaheen HM; Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
  • Rauf A; Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, Egypt.
  • Al-Kuraishy HM; Department of Chemistry, University of Swabi, Swabi 23561, Pakistan.
  • Qusti S; Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriyia University, P.O. Box 14022 Baghdad, Iraq.
  • Alshammari EM; Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Ayikobua ET; Department of Chemistry, College of Sciences, University of Ha'il, Ha'il 2440, Saudi Arabia.
  • Ssempijja F; School of Health Sciences, Soroti University, Soroti P.O. Box 211, Uganda.
  • Afodun AM; Department of Anatomy, Faculty of Biomedical Sciences, Kampala International University, Western Campus, Bushenyi P.O. Box 71, Uganda.
  • Kenganzi R; Department of Anatomy and Cell Biology, Faculty of Health Sciences, Busitema University, Tororo P.O. Box 236, Uganda.
  • Usman IM; Department of Medical Laboratory Sciences, School of Allied Health Sciences, Kampala International University Teaching Hospital, Bushenyi P.O. Box 71, Uganda.
  • Ochieng JJ; Department of Anatomy, Faculty of Biomedical Sciences, Kampala International University, Western Campus, Bushenyi P.O. Box 71, Uganda.
  • Osuwat LO; Department of Anatomy, Faculty of Biomedical Sciences, Kampala International University, Western Campus, Bushenyi P.O. Box 71, Uganda.
  • Matama K; School of Health Sciences, Soroti University, Soroti P.O. Box 211, Uganda.
  • Al-Gareeb AI; School of Pharmacy, Kampala International University, Western Campus, Bushenyi P.O. Box 71, Uganda.
  • Kairania E; Department of Pharmacology, Toxicology and Medicine, College of Medicine Al-Mustansiriya University, Baghdad P.O. Box 14022, Iraq.
  • Musenero M; Department of Anatomy and Cell Biology, Faculty of Health Sciences, Busitema University, Tororo P.O. Box 236, Uganda.
  • Welburn SC; Ministry of Science Technology and Innovations, Government of Uganda, Kampala P.O. Box 7466, Uganda.
  • Batiha GE; Infection Medicine, Deanery of Biomedical Sciences, College of Medicine and Veterinary Medicine, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.
Life (Basel) ; 11(8)2021 Jul 23.
Article in English | MEDLINE | ID: covidwho-1325726
ABSTRACT
Novel therapies for the treatment of COVID-19 are continuing to emerge as the SARS-Cov-2 pandemic progresses. PCR remains the standard benchmark for initial diagnosis of COVID-19 infection, while advances in immunological profiling are guiding clinical treatment. The SARS-Cov-2 virus has undergone multiple mutations since its emergence in 2019, resulting in changes in virulence that have impacted on disease severity globally. The emergence of more virulent variants of SARS-Cov-2 remains challenging for effective disease control during this pandemic. Major variants identified to date include B.1.1.7, B.1.351; P.1; B.1.617.2; B.1.427; P.2; P.3; B.1.525; and C.37. Globally, large unvaccinated populations increase the risk of more and more variants arising. With successive waves of COVID-19 emerging, strategies that mitigate against community transmission need to be implemented, including increased vaccination coverage. For treatment, convalescent plasma therapy, successfully deployed during recent Ebola outbreaks and for H1N1 influenza, can increase survival rates and improve host responses to viral challenge. Convalescent plasma is rich with cytokines (IL-1ß, IL-2, IL-6, IL-17, and IL-8), CCL2, and TNFα, neutralizing antibodies, and clotting factors essential for the management of SARS-CoV-2 infection. Clinical trials can inform and guide treatment policy, leading to mainstream adoption of convalescent therapy. This review examines the limited number of clinical trials published, to date that have deployed this therapy and explores clinical trials in progress for the treatment of COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Article Affiliation country: Life11080734

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Article Affiliation country: Life11080734